



## **Hydra Biosciences to Present at Needham & Company's 15th Annual Healthcare Conference on April 13**

**April 7, 2016 – Cambridge, MA** – [Hydra Biosciences](#), a leader in the field of Transient Receptor Potential (TRP) ion channel modulation to treat pain, inflammation, renal disease, CNS and pulmonary diseases, today announced that Russell Herndon, President and CEO, will provide a company update at [Needham & Company's 15th Annual Healthcare Conference](#). The presentation is April 13, 2016 at 11:40 a.m. EST at the Westin Grand Central in New York City.

Needham & Company's 15th Annual Healthcare Conference brings together institutional investors and venture capital firms with management teams from more than 100 biotechnology, specialty pharmaceutical, medical technology and diagnostic companies. The focus of this invitation-only conference is to connect leading public and private life science companies with investors.

### **About Hydra Biosciences**

Hydra Biosciences is a privately held biopharmaceutical company based in Cambridge, Massachusetts, that develops drugs to treat pain, inflammation, renal disease, CNS and pulmonary disease using its expertise in novel ion channels. Hydra Biosciences' proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: [www.hydrabiosciences.com](http://www.hydrabiosciences.com). Follow the company [@HydraBio](#).

###

### **Corporate:**

Russell Herndon  
Hydra Biosciences  
617-494-5230 x3352

### **Media Contact:**

David Connolly  
LaVoieHealthScience  
617-374-8800, Ext. 108  
[dconnolly@lavoiehealthscience.com](mailto:dconnolly@lavoiehealthscience.com)